Labcorp’s Assortment of Abstracts on Precision Oncology Featured at 2024 ASCO Annual Meeting

Labcorp, a renowned provider of cutting-edge laboratory services globally, is set to unveil multiple abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 31 to June 4, 2024. The presentations will underscore Labcorp’s commitment to advancing insights crucial for understanding tumor biology and immune system mechanisms, ultimately aiming to enhance patient outcomes through novel targeted therapies.

Dr. Shakti Ramkissoon, Labcorp’s Vice President and Medical Lead for Oncology, emphasized the company’s dedication to unraveling cancer biology complexities and refining therapeutic approaches. The studies to be presented cover critical areas such as triple-negative breast cancer (TNBC), liquid biopsy, and the application of advanced machine learning algorithms for tumor profiling, promising more precise diagnostics and treatments.

Of the eight abstracts scheduled for presentation, four originate from Labcorp’s internal research efforts, while the remaining four stem from collaborations with esteemed academic institutions and medical centers.

Among Labcorp’s contributions, two studies delve into various facets of TNBC, shedding light on factors influencing tumor progression and therapy resistance. Given TNBC’s disproportionate impact on Black women in the U.S., these insights are particularly significant.

The first study explores the interaction between Vascular Endothelial Growth Factor (VEGF) and immune checkpoint targets in TNBC, uncovering mechanisms of immune evasion and tumor progression. The second study investigates a novel phenotype associated with immune evasion in TNBC, offering potential strategies to overcome immunotherapy resistance.

Additionally, Labcorp researchers will present findings on a machine learning algorithm designed to detect tumor microsatellite instability (MSI) in patients with solid tumors, and a validation study of the Labcorp® Plasma Complete™ test, showcasing its precision and reliability in comprehensive genomic profiling through liquid biopsy.

To engage with Labcorp at the ASCO Annual Meeting, visit

Labcorp (NYSE: LH) is a global leader in laboratory services, empowering healthcare stakeholders to make informed decisions. With a workforce of over 67,000 serving clients in approximately 100 countries, Labcorp’s diagnostics and drug development capabilities drive advancements in healthcare, supporting a vast array of medical innovations and improving countless lives worldwide.

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter